Beginning Jan. 1, 2026, Lisdexamfetamine (generic Vyvanse) will be preferred on the BCBSND Formulary and Health Insurance Marketplace (HIM) formulary. Brand name Vyvanse will be a non-formulary/non-preferred medication on these formularies starting Jan. 1, 2026.
Current Vyvanse utilizers on the Blue Cross Blue Shield of North Dakota (BCBSND) or HIM formularies will be allowed to continue filling Vyvanse at the formulary rate until March 31, 2026. As this is a brand-to-generic change, new prescriptions should not be needed at the pharmacy.
This formulary update does not impact the NetResults formulary as Lisdexamfetamine is already the formulary agent and Vyvanse is non-formulary.
